Increased activation-induced cell death of high IFN-γ–producing TH1 cells as a mechanism of TH2 predominance in atopic diseases - 15/08/11
Abstract |
Background |
A dysregulated and TH2-biased immune response appears to be a key pathogenetic factor in atopic diseases. Increased activation and massive infiltration of T cells in the dermis without any evidence for the expansion of their numbers in peripheral blood characterize atopic dermatitis.
Objective |
To investigate differences and mechanisms of TH1 and TH2 cell activation-induced cell death (AICD) in atopic disease.
Methods |
Naive (CD4+CD45+RA) and memory (CD4+CD45+RO) T cells were isolated from healthy and atopic individuals. TH1 and TH2 subsets were in vitro differentiated. High IFN-γ–producing T cells and CXCR3+ T cells were purified, and AICD of isolated cells was determined in addition to expression of apoptosis receptors and caspase activation.
Results |
TH1 cells, particularly their high IFN-γ–producing fraction, and CXCR3+ T cells showed significantly increased apoptosis in atopic individuals. During their in vitro differentiation, both TH1 and TH2 cells of atopic individuals showed increased apoptosis compared with the healthy control group, with a significantly high apoptosis in TH1 cells. Increased expression of Fas, Fas-ligand, tumor necrosis factor receptor-II, and caspase activation was detected on TH1 cells that underwent apoptosis. Neutralization experiments demonstrated a dominant role of IFN-γ and Fas–Fas-ligand interaction-mediated suicide in TH1 cell AICD.
Conclusion |
Predominant TH2 profile in atopic diseases might be a result of the increased tendency to activation and apoptosis of high IFN-γ–producing TH1 cells.
Le texte complet de cet article est disponible en PDF.Key words : T cells, activation-induced cell death, apoptosis, atopy, TH1 cells, CXCR3
Abbreviations used : 7AAD, AD, AICD, CLA
Plan
Supported by Swiss National Foundation grants 32-118226 and 32-112306, the Global Allergy and Asthma European Network, and Dutch Asthma Foundation grant 3.2.03.17 2000. |
|
Disclosure of potential conflict of interest: C. A. Akdis has consulting arrangements with GlaxoSmithKline, 3M Pharma, and Aventis; has received research support from ALK-Abelló, Stallergenes, Allergopharma, Essex Chemie, the Swiss National Science Foundation, and GA2LEN; and is on the speakers’ bureau for Stallergenes, Allergopharma, and Merck. The rest of the authors have declared that they have no conflict of interest. |
Vol 121 - N° 3
P. 652 - mars 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?